Skip to content

Tumour ECM-targeted Tumour Necrosis Factor (TNF) alpha

A new targeted immunocytokine agent; TNF-CSG reduces tumour interstitial pressure, and increases tumour perfusion

Published: 27th January 2020
Tumour ECM-targeted Tumour Necrosis Factor (TNF) alpha
Please note, header image is purely illustrative. Source: Nephron, WikimediaCommons, CCbySA3.0
Patents
  • US and EP applications claim CSG-conjugated cytokine compositions-of-matter and methods of use. All claims are reported by the ISR and Written Opinion to be novel and inventive
IP Status
  • Patent application submitted
Seeking
  • Licensing
  • Development partner